加载中
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
收盘时
US$3.27
−US$0.05 · -1.51%
盘后
US$3.25
−US$0.02 · -0.61%
10月12日 16:06 ET
盘中时间采用ET。市场数据可能有所延迟。
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
日内区间
当前US$3.27
52周区间
当前US$3.27
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
57
合理估值
情绪
44
多空交织
风险
69
高风险
动量
30
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
日内区间
当前US$3.27
52周区间
当前US$3.27
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 70.59万 USD | 46.43万 USD | 22.62万 USD | 25.54万 USD | 72.27万 USD |
| 销货成本 | 2720 USD | 4822 USD | 3.15万 USD | 7.18万 USD | 17.53万 USD |
| 毛利 | 70.32万 USD | 45.95万 USD | 19.47万 USD | 18.36万 USD | 54.74万 USD |
| 研究与开发 | 823.88万 USD | 236.06万 USD | 366.67万 USD | 184.27万 USD | 126.29万 USD |
| 销售、一般及管理费用 | 434.52万 USD | 385.2万 USD | 306.2万 USD | 495.99万 USD | 497.13万 USD |
| 营业费用 | 1258.39万 USD | 621.26万 USD | 672.87万 USD | 680.26万 USD | 623.42万 USD |
| 利息收入 | 3017 USD | 1.43万 USD | 4.32万 USD | — | — |
| 折旧和摊销 | 8.78万 USD | 7.62万 USD | 14.54万 USD | 10.27万 USD | 14.76万 USD |
| 营业利润 | −1188.07万 USD | −575.31万 USD | −653.4万 USD | −661.9万 USD | −568.69万 USD |
| 净利润 | −1190.18万 USD | −579.53万 USD | −666.49万 USD | −726.93万 USD | −402.7万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$1.50
下跌空间 54.13%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月3日 | 1:15 | — | — |
股票拆分 | 2021年1月12日 | 1:30 | — | — |
股票拆分 | 2015年12月16日 | 11:10 | — | — |
股票拆分 | 2009年6月30日 | 1:4 | — | — |
已生效 2026年8月3日
1:15
已生效 2021年1月12日
1:30
已生效 2015年12月16日
11:10
已生效 2009年6月30日
1:4
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
